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Left atrial functionObjectives: Left atrial (LA) function is an important marker of hemodynamic status in cardiac amyloidosis
(CA), and its characterization may provide relevant prognostic information. We sought to assess the
prevalence and prognostic impact of LA dysfunction by cardiac magnetic resonance (CMR) in patients
with CA.
Methods: We performed CMR in 80 consecutive patients with CA, including 38 with AL (47%) and 42 with
ATTR (53%). LA function was assessed by acquiring short axis cine steady-state free precession (SSFP) cov-
ering the entire chamber. The atrial emptying fraction (AEF) was calculated as the ratio between the dif-
ference of LA maximal and minimal volume to LA maximal volume, expressed as percentage. Severe atrial
dysfunction was defined as AEF  14%.
Results: Mean AEF was 18% (13–35%). Overall, AEF  14% was present in 19 patients (24%), including 21%
of those in sinus rhythm (SR) with no history of atrial fibrillation (AF). After a median of 3 years (IQR 2–4),
36 patients (44%) died of cardiac causes. Patients with AEF  14% showed increased cardiac mortality,
with an independent OR of 4.2 (95 IC 2.1–8.2, P < 0.0001). Of note, AEF  14% was the stronger indepen-
dent predictor of cardiac death. Patients in SR with AEF  14% had worse outcome than those with AF.
Conclusions: Severe impairment of LA contractile function was present in three-quarters of patients with
CA, and was prevalent irrespective of CA etiology, both in the presence and absence of AF. Severe LA dys-
function was associated with an independent 4-fold increase in risk for cardiac death at three years.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiac amyloidosis (CA) is characterized by extracellular accu-
mulation of fibrillary proteins within the myocardium, leading to
progressive infiltration and functional impairment [1]. CA begins
with a subclinical stage characterized by mild and non-specific car-
diac symptoms [2]. Progression of amyloid deposition causes
marked thickening of the cardiac walls leading to subsequent
stages of heart failure with preserved systolic function (HFpEF)
and different grades of diastolic dysfunction. The end-stage of CA
is characterized by congestive HF with biventricular systolicimpairment, atrial fibrillation (AF) or sinus node dysfunction and
atrioventricular block [3].
While the ventricular manifestations of CA dominate the clini-
cal picture, the disease is known to affect the heart as a whole,
including the left atrium (LA), interatrial septum and valvular
apparatus. Amyloid deposition has been documented in the atrial
walls and may create dysfunction [4]. LA remodeling and func-
tional impairment, although different in etiology and molecular
substrates, is a well-established epiphenomenon of many cardiac
diseases, including pathophysiologic models resembling CA, such
as hypertrophic cardiomyopathy (HCM). In HCM, both LA size
and systolic function represent important predictors of outcome
[5]. However, whether this concept may be applied to CA is still
unresolved. The issue has a number of potential implications in
clinical practice, ranging from screening and stratifying for disease
severity to evaluating likelihood of AF. Cardiac magnetic resonance
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function. The present study aimed to exploit the potential of CMR
in CA patients to 1) evaluate the prevalence of LA dysfunction
through the analysis of LA volume\time curve, both in patients in
sinus rhythm and AF, and 2) evaluate its independent clinical
and prognostic.2. Methods
We enrolled 80 consecutive patients (mean age 70 ± 12 years,
56 males) with an established diagnosis of CA: 38 patients with
systemic AL amyloidosis (47%); 13 with genetic amyloidosis due
to ATTR mutations (16%); 29 with wild type ATTR amyloidosis
(37%). Diagnosis of AL amyloidosis was confirmed by biopsy of
abdominal fat pad or of an involved organ. Amyloid deposits
demonstrated typical Congo Red birefringence under polarized
light and were characterized as AL type by immunohistochemistry
on optic or immunoelectron microscopy or proteomics analysis
according to the time of diagnosis. A monoclonal light chain of
the same isotype (j or k) as that found in the amyloid deposits
needed to be detected in serum and/or urine by immunofixation
and by circulating FLC quantitation. A diagnosis of ATTR was made
after evidence of documentation of Congo-red staining and apple-
green birefringence under cross-polarized light in at least one
involved organ followed by TTR deposits typing by immunohisto-
chemistry on optic or immunoelectron microscopy or proteomics
analysis according to the time of diagnosis in a positive tissue
biopsy; (b) non-invasive documentation of intense cardiac uptake
(visual score 2 or 3) on bone tracer scintigraphy with 99mTc-
HMDP in the absence of either an abnormal serum free light chain
ratio or a monoclonal protein in the serum or urine by immunofix-
ation [6]. Diagnosis of CA was confirmed by myocardial biopsy
(Congo-red staining combined with polarized light) and/or by the
presence of CMR morphologic and post-contrast criteria of CA [7]
or cardiac 99mTc-HMDP retention. The study was approved by
the institutional ethical committee, and all subjects gave their
written informed consent.
All patients underwent a thorough clinical, biohumoral, electro-
cardiographic and echocardiographic evaluation at enrollment.
Presence and the severity of dyspnea was classified by New York
Heart Association (NYHA) functional class. Biomarkers included
serum creatinine, troponine I and plasma NT-proBNP assay.
Patients with contraindications to CMR and those with an esti-
mated glomerular filtration rate (eGFR) < 30 ml/min, by Cockroft
Gault formula were excluded from the study.2.1. CMR protocol
CMR was performed with a dedicated 1.5-T (Signa Artist, Gen-
eral Electrics Healthcare, Milwaukee, Wisconsin) with a 16-
channel cardiac phased array coil. Short-axis cine images were
acquired orthogonal to main LV axis covering both LV and LA, using
a steady-state free precessing FIESTA (fast imaging employing
steady-state acquisition) pulse sequence with the following
parameters: 30 phases, slice thickness 8 mm, no gap, 8 views per
segment, number of excitation 1, field of view 40 cm, phase field
of view 1, 224  224 matrix, voxel dimensions 1.78  1.78  8 m
m, reconstruction matrix 256  256, 45 flip angle, repetition time/
echo time equal to 3.5/1.5, and a bandwidth of 125 KHz. After cine
imaging, 0.2 mmol/kg Gadoteridol (Prohance, Bracco Imaging)
were administered and late gadolinium enhancement (LGE)
images acquired approximately 10 after the administration of the
contrast medium in a full set of short-axis views in the same plane
of cine images. The following parameters were used: field of view
35–40 cm, slice thickness 8 mm, no gap between each slice, repe-2
tition time 4.6 ms, echo time 1.3, 20 flip angle, matrix 224  224,
reconstruction matrix 256  256, number of excitations 1. A mod-
ified Look-Locker Imaging (MOLLI) pulse sequence with 3(3)3(3)5
pattern was used to evaluate native T1 in 3 (basal, middle and api-
cal) short axis slices.
2.2. Image analysis and definition of atrial emptying fraction (AEF)
Analysis of CMR images was performed, using a commercially
available research software package (CMR42, Circle). Endocardial
and epicardial contours of LV and RV myocardium were traced in
the end-diastolic and end-systolic phases. End-diastolic and end-
systolic volume indexes, biventricular mass and mass index were
measured as previously described [8]. The presence of typical
LGE pattern for CA was evaluated by three expert level-III EACVI
accredited observers, blinded to each other [9].
Parameters of LA function were evaluated as previously
reported [8]. Briefly, LA endocardial contours were automatically
traced in every cine frame to obtain volumetric data of all cardiac
phases. Manual correction was performed when needed. Volumet-
ric data were plotted against time (in ms) generating a LA volume
over time (V/t) curve (Fig. 1). Through the analysis of the atrial V/t
curves, atrial emptying volume was measured as the difference
between the maximal and minimal atrial volumes. The atrial emp-
tying fraction (AEF) was then measured as the ratio between atrial
emptying volume and maximal atrial volume, expressed in %. The
atrial reservoir, conduit and booster volumes were measured in ml.
As reported in the previously mentioned study [8] in healthy con-
trols AEF was > 36% and this was considered the cut-off for pre-
served LA function. Using this threshold, patients were divided in
those with preserved and those with impaired LA function
(AEF  36%). Patients with impaired LA function, were further
divided in 3 groups based on tertiles of AEF found in our cohort:
severe (AEF  14%), moderate (>14% to 20%), and mild dysfunc-
tion (>20%36%).
2.3. Clinical follow-up and study end-point
All patients were followed-up after CMR. A clinical question-
naire was compiled by an expert physician during periodic ambu-
latory visitations in each hospital, by contacting their relatives by
telephone, by a general practitioner, or by consulting the office of
vital statistics at the patient’s place of residence. The end-point
of the study was death due to cardiac causes (heart failure or sud-
den cardiac death).
2.4. Statistical analysis
Values are presented as the mean ± SD or as the median and
interquartile range (IQR) for variables with normal and non-
normal distributions, respectively. Values with non-normal distri-
bution according to the Kolmogorov-Smirnov test were logarithmi-
cally transformed for parametric analysis. Qualitative data are
expressed as percentages. Categorical variables by the Chi-square
or by the Fisher exact test. Continuous variables were compared
by the ANOVA with Bonferroni correction when needed, or with
Wilcoxon non-parametric test as appropriate. ROC curve analysis
was used to found the more accurate threshold of AEF for predict-
ing cardiac death. The Kaplan-Meier time-to-event method was
employed to calculate and compare longitudinal curves between
groups. Univariate and Multivariate COX regression analysis (step-
wise) was used to explore the impact of each significant variable to
predict the occurrence of cardiac death). The risk of multicollinear-
ity among the covariates was evaluated by the variance inflation
factor (VIF). VIF values were <10 for all the variable included in
Fig. 1. Left atrial Volume\Time curves: Examples of left atrial volume\time curve in a healthy control, upper panel and in a patient with cardiac amyloidosis.
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p-value < 0.05 was considered statistically significant.3. Results
A total of 80 patients with mean age 70 ± 12 years, 56 males
(69%) were enrolled in the study, including 57 patients (71%) in
SR and 23 (29%) in AF. Of these 80 patients, 19 had severe LA dys-
function (AEF  14%), 21 moderate (AEF > 14% to 20%), and 20
mild dysfunction (AEF > 20%36%); the remaining 20 patients
had normal AEF values (Table 1). Notably, AEF  14% was found
in 12 of the 57 (21%) patients in sinus rhythm. Patients with severe
LA dysfunction (AEF  14%) had higher NT-pro-BNP values, higher
wall thickness and atrial volume than those with preserved LA
function. An inverse relation was found between AEF and NT-
pro-BNP (R2 0.24, p = 0.015). Patients with aTTR amyloidosis were
older (64 ± 12 vs 76 ± 10 years, p < 0.001), had higher wall thick-
ness (14 ± 4 vs 17 ± 5 mm, p = 0.007), higher LV mass index
(88 ± 27 vs 121 ± 38 g/m2, p < 0.001) and greater atrial maximal
volume (120 ± 33 vs 140 ± 42 ml/m2, p < 0.02) than those with
AL. However, AEF was not significantly different between AL and
aTTR.3
3.1. Clinical Follow-up
During a median follow up of 3 (2–5) years, 36 patients died
(44%) of cardiac causes. At baseline, patients with cardiac death,
compared to survivors, had higher TnI-HS values 95 vs 52 pg/dl);
p < 0.05), lower RVEF (54%vs 60%; p < 0.05), higher LA maximal
(146 vs 120 ml; p < 0.05) and minimal volume (124 vs 90 ml;
p < 0.005), lower LA reservoir (18 vs 28 ml; p < 0.005) and booster
volumes (12 vs 18 ml; p < 0.005) and lower AEF (14 vs24;
p < 0.001). At ROC curve analysis, AEF predicted cardiac death with
an AUC of 0.72 (95% CI 0.60–0.82; p = 0.0002). The best AEF thresh-
old for cardiac death prediction was 14% (sensitivity 60%, speci-
ficity 86%). The relation between AEF and the maximal atrial
volume is showed in Fig. 2. Kaplan Meier survival analysis identi-
fied impaired survival in patients with AEF  14% compared to
patients with AEF > 14% (Log rank p < 0.0001) as depicted in
Fig. 3 (left panel). At univariate Cox regression analysis, NYHA
class, NT-proBNP, troponin I, RVEF, maximum atrial volume, AEF
and AEF  14% were associated with cardiac death (Table 2). Mul-
tivariable Cox regression analysis was performed in two different
models, the first including AEF as continuous variable, the second
with AEF  14% as dichotomous parameter. In the first model
NYHA class and AEF were independent predictors of cardiac death,
Table 1
Prevalence and clinical correlates of left atrial (LA) systolic dysfunction in 80 patients with cardiac amyloidosis.
Overall
population







AEF  14% 15–20% 20– 36% > 36%
n. 80 19 21 20 20
AL/ATTR 38/42 10 (53%)/9 (47%) 6 (29%)/15 (71%) 9 (45%)/11 (55%) 13 (65%)/7 (35%) 0.10.
Age (y) 70 ± 12 71 ±12 73 ±10 73 ±8 63 ±15 <0.05
Males n (%) 56 (69%) 14 (70%) 17 (81%) 16 (80%) 9 (45%) 0.051
Height (cm) 169 ± 8 169 ±8 170 ±6 171 ±6 167 ±10 0.35
Weight (Kg) 73 ± 12 74 ±11 74 ±12 72 ±14 70 ±13 0.74
BSA (m2) 1.83 ± 0.18 1.85 ±0.15 1.86 ±0.16 1.84 ±0.2 179 ±0.19 0.64
NYHA I 14 0 4 (20%) 5 (28%) 5 (25%) 0.07
NYHA II 37 4 (20%) 9 (43%) 9 (43%) 15 (75%) <0.05
NYHA III 29 15 (80%) 8 (37%) 6 (29%) 0 <0.05
NT-proBNP (pg/ml) 1984 (859–8185) 9531(2022–11251) 4 1901(920–4775) 2207(9585–9659) 624(521–856) 1 <0.05
Troponine I hs (pg/dl) 66 (47–101) 100(95–106) 50(33–66) 51(34–65) 51 (34–51) 0.11
Atrial fibrillation 23(28%) 8(42%) 9(43%) 4(20%) 2(10%) 0.048
IVS (mm) 16 ± 5 19 ±54 17 ±44 16 ±44 11 ±31,2,3 <0.001
PW (mm) 12 ± 4 15 ±34 13 ±34 12 ±34 8 ±21,2,3 <0.001
LVEF (%) 58 ± 11 56 ±11 53 ±84 58 ±13 65 ±102 <0.05
LVEDVi (ml/m2) 75 (63–91) 81 ±38 87 ±27 78 ±20 81 ±29 0.79
LV SV (ml/m2) 31 (23–40) 82 ±25 88 ±29 81 ±17 91 ±19 0.52
Mass index (g/m2) 105 ± 41 119 ±414 119 ±324 109 ±474 72 ±241,2,3 <0.001
LGE specific for CA diagnosis
n(%)
53 (65%) 12 (65%) 18 (86%) 13 (65%) 13 (65%) 0.06
WMSI 1 (1–1.35) 1.34 ±0.4 1.30 ±0.4 1.18 ±0.4 1.10 ±0.3 0.15
Maximal Atrial volume (ml) 122 (95–160) 162 ±514 151 ±474 128 ±424 83 ±221,2,3 <0.01
Minimal Atrial Volume (ml) 101 (63–144) 149 ±473,4 128 ±403,4 95 ±331,2,4 45 ±151,2,3 <0.01
AEF, atrial emptying fraction; AL, light chain amyloidosis; ATTR, transthyretin amyloidosis; NYHA, New York Heart Association; BSA, body surface area; IVS, interventricular
septum; PW, posterior wall; LVEF, left ventricle ejection fraction; LV EDVi, left ventricle end diastolic volume index; LV SV, left ventricle stroke volume; LGE, late gadolinium
enhancement; WMSI, wall motion score index.
1
significant p value vs severe LA dysfunction.
2
significant p value vs Moderate LA dysfunction.
3
significant p value vs Mild LA dysfunction.
4
significant p value vs Preserved LA function.
Fig. 2. Relation between the atrial emptying fraction (AEF) and the maximal atrial volume: A significant inverse relation was found between AEF and the maximal atrial
volume (r = 0.61, p < 0.0001), but some patients had low AEF with only mild atrial dilation. In left panels patients were divided by the type of amyloidosis (AL, mutated-
aTTR, wild type-aTTR). In right panel, patients were divided by cardiac death or not.
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predictors.
3.2. Sinus rhythm vs atrial fibrillation
Among patients in SR, Kaplan Meier survival analysis showed
that the presence of AEF  14% was associated to worse prognosis
than those with AEF > 14% (Log rank < 0.0001, Fig. 3, right panel).
In contrast, among patients in AF, no significant difference in sur-
vival was found between AEF > 14% and AEF  14%. Interestingly,4
patients in SR and AEF  14% had higher risk of cardiac death than
those with AF: 1- year risk of cardiac death, respectively 42% (95%
CI 40–43) vs 17% (95% CI 16–18), p < 0.0001; 3-year risk, respec-
tively 75% (95% CI 72–78) vs 42% (95%CI 40–43), p < 0.0001.
4. Discussion
The main findings of the present study can be summarized as
follows: a) left atrial dysfunction is common in CA patients, and
can be severe even in the presence of stable SR; b) when severe,
Table 2
Cox Logistic regression analysis for the risk of hard cardiac events.
Univariate
HR 95% CI p value
Age 1.8 0.8–7.4 0.08
NYHA Class (III) 2.3 1.4–3.8 0.001
HS Troponine I 1.05 1.2–3.02 0.017
NT-proBNP 1.4 1.2–4.5 0.004
AL/TTR 1.18 0.6–2.3 0.6
LV EF 1.74 0.87–3.5 0.12
LV EDVi 1.5 0.61–3.9 0.36
LV mass index 1.9 0.98–3.8 0.06
RVEF (%) 0.97 0.95–0.99 0.013
RV EDVi 1.16 0.46–2.9 0.73
LA maximal Volume 1.01 1–1.01 0.0008
AEF 0.94 0.91–0.97 0.0009
AEF  14% 4.1 2.08–8.1 <0.0001
Model with AEF (continuous) Multivariate
HR 95% CI p value




AEF 0.9 0.9–0.98 0.005
Model with AEF  14% (dichotomic) Multivariate
HR 95% CI p value




AEF  14% 4.0 2.0–7.9 <0.0001
LV, left ventricle; RV, right ventricle; EDVi, end-diastolic volume index; EF, ejection
fraction; LA, left atrium; AEF, atrial ejection fraction, HS, High-sensitivity.
Only parameters with p value <0.05 at univariate were included in multivariate
analysis.
Fig. 3. Prognostic differences between patients with and without atrial dysfunction. In left panel, Kaplan Meier curve demonstrating that patient with impaired left atrial
function with atrial emptying fraction (AEF)  14% had worse prognosis than those with better function. In right panel, Kaplan Meier curve demonstrating that patient with
atrial fibrillation had worse prognosis than those with sinus rhythm and atrial emptying fraction (AEF) > 14%, but the worst prognosis is showed in patient with sinus rhythm
and AEF  14%.
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increase in cardiac mortality, representing a powerful independent
predictor of risk; c) the prognosis of CA patients in SR with5
AEF  14% is worse than that of patients in AF. Severe LA dysfunc-
tion, defined as AEF  14% was a strong independent predictor of
cardiac death. Patients with AEF  14% had a 32% risk at 1 year
and a 61% risk at 3 years. The identification of AEF by CMR is a sim-
ple, accurate and reproducible parameter that can facilitate risk
stratification and prognosis assessment in patients with AL and
ATTR CA. Furthermore, phasic measurement of LA function using
feature-tracking CMR add important information regarding LA
fibrosis and provide additional insight for procedural outcomes
and stroke risk stratification [23]. In HF patients, Pellicori et al
[21] found that left atrial function measured by CMR was an
important marker of cardiac dysfunction and cardiovascular out-
come. In that study, AEF was associated with increasing plasma
concentrations of NT-proBNP and a higher incidence of AF and
was a predictor of adverse outcome independently of other param-
eters of cardiac dysfunction. Mohty et al [22] observed an associa-
tion of AEF with severity of cardiac involvement, functional status
and presence of LGE in patients with AL CA.
LA is a ‘‘victim” of CA for a number of reasons. First, the deposi-
tion of amyloid proteins causes an increase in LV stiffness and dias-
tolic dysfunction that determines LA dilatation, and ultimately
precipitates AF and electromechanical dysfunction. Second, amy-
loid directly affects the LA wall reducing atrial contractility and
contributing to the impairment of LV filling. Henein et al. analyzed
LA strain by 2D echocardiography in 46 patients with CA [16]. They
found that, despite normal chamber size, LA myocardial deforma-
tion function was depressed, suggesting that infiltration with amy-
loid fibrils could limit LA distension and primarily affecting the
atrial booster phase.
Notably, although severe atrial dysfunction was more prevalent
(48%) among CA patients in AF, it was far from rare among in sinus
rhythm (involving one in five or 21%). While patients in SR and pre-
served atrial function expectedly showedmore favorable prognosis
than those in AF, patients with SR and severe atrial dysfunction had
the worst outcome of all. Although the small sample size warrants
caution in its interpretation, this finding suggests that LA dysfunc-
tion per se carries sufficient hemodynamic burden to cause clinical
deterioration without the mediation of AF; this may also reflect the
G.D. Aquaro et al. IJC Heart & Vasculature 31 (2020) 100633fact that loss of atrial contribution in these stages of CA is irrele-
vant and does not carry adverse consequences when lost to AF:
The other explanation is that severe atrial dysfunction in SR might
be a marker of severe atrial amyloid deposition inducing atrial
standstill with preserved electrical conduction, in a sort of regional
electromechanical dissociation reflecting particularly severe car-
diac involvement. This observation deserves further investigation
as it largely counters what is seen in other forms of heart failure
and cardiomyopathies including HCM. Finally, severe atrial dys-
function in the presence of SR has important management implica-
tions, including a potentially high cardioembolic risk even in the
absence of AF. The fact that we did not observe stroke or other
embolic complications does not exclude this possibility, as shown
in previous studies on CA patients in sinus rhythm [18,19,20].
Some study limitations should be mentioned. First, the study
population patients was relatively small (n = 80) and allowed lim-
ited power for subanalyses (including different CA etiologies). Sec-
ond, we did not employ dedicated software for atrial function
assessment such as, feature tracking. The choice to evaluate atrial
function using only atrial volume was aimed at obtaining an easily
reproducible parameter available with every clinical CMR scanner
without the need for complex and expensive post-processing
software.
5. Conclusions
Severe impairment of LA contractile function was present in
three-quarters of patients with CA, and was prevalent irrespective
of CA etiology, both in the presence and absence of AF. Severe LA
dysfunction was associated with an independent 4-fold increase
in risk for cardiac death at three years. AEF is easily obtainable
and should be considered routinely in CA patients undergoing
CMR.
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